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Application of M13 phage display for
identifying immunogenic proteins from tick
(Ixodes scapularis) saliva
Martin Becker1,2,3, André Felsberger1,4, André Frenzel1, Wendy M. C. Shattuck2, Megan Dyer2, Jonas Kügler1,
Jonas Zantow1, Thomas N. Mather2† and Michael Hust1*†
Abstract
Background: Ticks act as vectors for a large number of different pathogens, perhaps most notably Borrelia
burgdorferi, the causative agent of Lyme disease. The most prominent tick vector in the United States is the
blacklegged tick, Ixodes scapularis. Tick bites are of special public health concern since there are no vaccines
available against most tick-transmitted pathogens. Based on the observation that certain non-natural host animals
such as guinea pigs or humans can develop adaptive immune responses to tick bites, anti-tick vaccination is a
potential approach to tackle health risks associated with tick bites.
Results: The aim of this study was to use an oligopeptide phage display strategy to identify immunogenic salivary
gland proteins from I. scapularis that are recognized by human immune sera. Oligopeptide libraries were generated
from salivary gland mRNA of 18 h fed nymphal I. scapularis. Eight immunogenic oligopeptides were selected using
human immune sera. Three selected immunogenic oligopeptides were cloned and produced as recombinant
proteins. The immunogenic character of an identified metalloprotease (MP1) was validated with human sera. This
enzyme has been described previously and was hypothesized as immunogenic which was confirmed in this study.
Interestingly, it also has close homologs in other Ixodes species.
Conclusion: An immunogenic protein of I. scapularis was identified by oligopeptide phage display. MP1 is a
potential candidate for vaccine development.
Background
Pathogen transmission by ticks is a worldwide problem
that causes significant health risks and economical losses
[1]. The deer tick, Ixodes scapularis, which is prevalent
in the eastern and upper mid-western United States,
functions as a vector for a number of pathogens includ-
ing the Lyme disease spirochete, Borrelia burgdorferi, [2]
that the U.S. Centers for Disease Control estimates cur-
rently causes 300,000 new infections each year solely in
the United States [3, 4]. To date, preventing tick-
transmitted diseases relies mostly on the application of
acaricides and protecting against tick bites [5]. Currently,
no vaccines are available for most tick-transmitted
pathogens, emphasizing the health risks posed by tick-
bites. Pathogen transmission is substantially aided by bio-
active components of tick saliva providing anti-
inflammatory or anti-haemostatic effects amongst other
activities [6–8]. Several studies have demonstrated the im-
portance of specific tick salivary proteins in pathogen
transmission [2, 9]; pathogen transmission from tick vec-
tors is significantly more efficient compared to pathogen
transmission through a needle and syringe, underlining the
importance of tick saliva in this process [10].
It is noteworthy that the transcriptome of tick salivary
glands is highly dynamic and changes rapidly during
feeding [11]. Even more interesting is the observation
that early salivary proteins, those expressed within the
first 24 hours of feeding, appear to be sufficient to in-
duce an immune response in certain hosts [12] while
during this early phase of blood feeding, few if any path-
ogens are transferred from tick to host [2].
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Certain host animals can acquire immunity to tick
bites after repeated infestations [13–15]. Acquired tick
resistance (ATR) and the tick protective response can
manifest itself in many different ways. Among the valid
definitions listed in the literature are decreased numbers
of ticks successfully engorging on a host, premature tick
detachment, decreased oviposition or even death of the
tick as well as host hypersensitivity reactions [15, 16]. A
study focusing on basophils and mast cells as well as dif-
ferent Ig receptors on their surface showed that these
cell types as well as immunoglobulins of the IgG and the
IgE class are essential for acquired tick immunity [17].
Furthermore, acquired tick immunity also has been cor-
related with impaired pathogen transmission [18, 19], in-
spiring the concept of anti-tick vaccination. Such a
strategy could potentially alleviate human health risks by
preventing infection with a number of pathogens through
a single, vector-targeted approach to vaccination. Several
studies have begun assessing this idea, using serum anti-
bodies from tick sensitized animals as probes for identify-
ing immunogenic proteins in tick saliva, followed by
testing the vaccination potential of the identified antigens
in immunization studies [20, 21]. However, to our know-
ledge there is no study identifying tick salivary antigens as
potential vaccine candidates that are recognized specific-
ally by humans.
Phage display is a robust technique suited for high-
throughput screening of specific and high-affinity inter-
actions between biomolecules, especially proteins and
peptides such as antibodies and/or antigens [22–24].
Phage particles can directly be engineered to display for-
eign proteins on their surface while carrying the genetic
information inside their capsid, thus providing an intrin-
sic connection of genotype and phenotype [25, 26].
Phage display libraries are readily generated from gen-
omic DNA of prokaryotes and cDNA of eukaryotes. A
major burden during library construction is the high rate
of DNA fragments cloned out of frame with the phage
coat protein to be fused to for display [27]. This pitfall is
significantly relieved by the pHORF/Hyperphage system,
which includes an ORF enrichment step, improving the
efficiency of library packaging and subsequent screening
[28–31]. An overview about M13 phage display derived
technologies for selecting immunogenic proteins/bio-
markers is given elsewhere [32].
In this study a phage display antigen library composed
of cDNA derived from 18 h fed nymphal I. scapularis
salivary gland mRNA was generated. The goal was to
screen this library against IgG antibodies from human
donors that self-identified as having strong reactions to
tick bites, including redness and itching, pre-mature tick
detachment or even death of the tick. Proteins identified
in this screen are proposed to be useful in at least two
ways. First, these proteins might serve as future vaccine
candidates to immunize against tick bites and in this
way to prevent tick transmitted diseases. Second, the
presence of antibodies against these identified proteins
may be useful as biomarkers of tick exposure or recent
tick bites.
Results
Construction of an antigen library from salivary glands of
I. scapularis nymphs
In order to construct an antigen library containing pro-
teins which are relevant in anti-tick immunity [2], the
salivary glands of nymphal I. scapularis previously fed
for 18 h on a rodent host were dissected and mRNA was
extracted. This mRNA was reverse transcribed into
double-stranded cDNA using the SMART cDNA synthe-
sis Kit. In this protocol a PCR based amplification step is
performed to obtain larger quantities of double-stranded
cDNA of full-length transcripts from limited mRNA
sources. The salivary gland derived cDNA obtained by
this protocol revealed a size range from 100 bp to more
than 2000 bp (Fig 1a). Subsequently, this cDNA was
used to construct a phage display antigen library using
the pHORF3/Hyperphage system [28, 30]. Since UTRs
at the 5’ and the 3’ ends as well as stop codons are not
desired for subsequent cloning into the phagemid vector
pHORF3, a partial restriction enzyme digest using three
blunt end cutters was performed (data not shown). Fi-
nally, cDNA fragments were ligated into pHORF3 and E.
coli Top10F’ were transformed with this library. A
Colony-PCR was performed to assess the range of insert
sizes as well as the cloning efficiency. More than 90 % of
the analyzed clones contained an insert ranging from
50 bp to 700 bp (Fig 1b). 20 clones were subsequently
sequenced, verifying that inserts are containing tick sal-
ivary sequences (data not shown). Finally, the library di-
versity was determined to be 1 x 106 independent clones
as assessed by transformation efficiency.
Packaging of the library was performed using a help-
erphage lacking a functional gene encoding the pIII en-
velope protein called Hyperphage [30, 33]. Together
with the pHORF3 phagemid, this system allows for ORF
enrichment as only inserts which are in-frame with the pIII
gene of the phagemid will be expressed as oligopeptide-
pIII fusions and thus assemble infectious phage [28]. This
library was packaged yielding a final phage titer of 2 x
1011 CFU/ml, ensuring sufficient coverage for each of the
predicted 106 antigens of the library.
Analysis of human blood sera for SGH reactivity
For this study several human blood sera were obtained
from donors who classified themselves as either tick-bite
sensitive or tick-bite naive, the latter meaning that these
individuals had never been bitten by a tick, according to
their own statement. In contrast, tick-bite sensitive
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donors had been bitten multiple times and some re-
ported strong and instant responses such as itching or
rashes, which might also be triggered through humoral
immunity (Table 1).
An ELISA was performed to analyze these blood sera
for titers of antibodies recognizing tick salivary proteins.
Salivary gland homogenate (SGH) of I. scapularis nymphs,
fed for 18 h on a rodent host, was immobilized in the wells
of a microtiter plate. Next, dilution series of human donor
sera were tested for IgG antibodies recognizing the SGH.
As a negative control the same sera dilution series were
tested on blocked wells without SGH (Fig 2a-d). Note that
even donors who classified themselves as tick-bite naive
(i.e. donor 5) revealed some potential to recognize tick sal-
ivary proteins. On the contrary, some donors classified as
tick-bite sensitive performed poorly in this assay (i.e.
donor 4). According to this assay, donors 2 and 8 showed
very promising results with respect to the presence of
SGH specific immunoglobulins (Fig 2a and d).
Enrichment of anti-SGH specific antibodies from human
blood sera
Due to the complex nature of human blood sera, specific
antibodies recognizing tick salivary proteins were puri-
fied from promising sera, as judged by the first ELISA
analysis (Fig 2). This step was performed to increase the
specificity and thus the significance of the screening of
the phage display library (Fig 1) using highly concen-
trated and specific anti-SGH antibodies from tick-bite
sensitive donors.
For this purpose 18 h nymphal tick SGH was coupled
to magnetic carboxy beads. These beads were used in a
pull-down experiment with the sera of donors 2 (data
not shown) and 8, which were judged as high performers
according to Fig 2. After incubation with the sera, the
beads were washed, and bound antibodies were eluted.
The eluate was quantified and analyzed by ELISA for in-
creased binding efficiency to SGH, compared to the ori-
ginal serum as well as a negative control eluate obtained
from using blocked beads without SGH for the pull-
down (Fig 3). The experiment confirmed the presence of
highly specific IgG antibodies in the sera of donors 2
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Fig 1 a Agarose gel electrophoresis of cDNA obtained after SMART cDNA synthesis using mRNA from salivary glands of 18 h fed I. scapularis
nymphs. cDNA was subsequently used to construct the antigen library. b Colony PCR from randomly picked clones after cloning salivary gland
derived cDNA fragments into pHORF3 and transformation of E. coli Top10F’ to determine insert percentage and size distribution of the
antigen library
Table 1 Tick-bite status of the eight human blood donors used
in this study. Donors were categorized according to their own
statements to be either tick-bite naive (never bitten by a tick) or
tick-bite sensitized (bitten by ticks in the past)
Donor number Tick-Bite status
1 naive
2 sensitized
3 sensitized
4 sensitized
5 naive
6 naive
7 sensitized
8 sensitized
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and 8 recognizing tick salivary proteins. Based on the
confirmation of the presence of these antibodies, whole
serum samples as well as enriched anti-SGH specific
antibodies were used to screen our nymphal salivary
gland library using phage display to identify proteins
specifically recognized by these antibodies.
Phage display screening for immunogenic nymphal tick
salivary gland peptides
Immunogenic peptides from 18 h fed nymphal I. scapu-
laris were identified by screening the phage antigen library
against immunoglobulins of the IgG isotypes from human
blood sera using the pHORF3 system [28]. Here, two dif-
ferent strategies were utilized. First, IgG from whole sera
were captured and screened against the antigen library in
three consecutive panning rounds. Second, the same pro-
cedure was followed using the anti-SGH specific anti-
bodies previously enriched using the pull-down strategy
instead of the whole sera.
After three consecutive rounds of panning, a screening
ELISA was performed using the resulting enriched phage
clones to confirm the presentation of specifically recognized
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Fig 2 ELISA analysis to test the reactivity of serum IgG from eight different donors (a. donor 1+2, b. donor 3+4, c. donor 5+6, d. donor 7+8) to tick
salivary gland homogenate (SGH). SGH was immobilized in the wells of a microtiter plate and screened with a dilution series for each serum (solid
lines). Controls were performed with the same dilution series on blocked wells without SGH to determine unspecific background signals (dashed lines)
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Fig 3 Representative experiment for enrichment of SGH specific antibodies from serum of donor 8. SGH-coupled carboxy beads were incubated
with serum, washed and specifically binding antibodies were eluted. The eluted antibodies were quantified and tested for their reactivity to SGH
in an ELISA (black curve). Serum was also incubated with control beads without coupled SGH and eluted antibodies were tested for reactivity
with SGH in an ELISA (blue curve). Additionally, antibodies from whole serum without enrichment were tested (red curve)
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salivary peptides. Here, 92 clones were picked and mono-
clonal phages were produced in microtiter plates. These
phage particles were immobilized in the wells of a microti-
ter plate and analyzed for their reactivity with IgG from the
whole donor sera or enriched anti-SGH specific antibodies,
respectively (Data not shown and Fig 4). As a negative con-
trol Hyperphage was immobilized and screened accordingly
(Fig 4). Enriched peptides identified in this assay are sum-
marized in Tables 2 and 3. Of note, these peptides are the
result solely from screenings performed with sera from do-
nors 2 and 8. Interestingly, screenings performed with sera
from donors previously classified as tick-bite naive did not
lead to the enrichment of any of the clones given in Table 2
(data not shown).
Validating the immunogenic character of the identified
salivary proteins
Among the proteins identified (Table 2), four were se-
lected for recombinant production in E. coli BLR(DE3)
and subsequent validation of the immunogenic character
in a titration ELISA assay with all donor sera. The pro-
teins selected are Ixodes scapularis conserved hypothet-
ical protein (XM_002402723.1) because it had the most
significant enrichment throughout all screens, the
thrombin inhibitor (XM_002408067.1) due to its poten-
tial role in interfering with host blood coagulation, the
ubiquitin protein ligase (XM_002412768.1) since two
molecules of this type were selected, and the metallopro-
tease (AY_264367.1) since this protease has been dis-
cussed in the context of tick immunity previously [34].
Subsequent cloning of the I. scapularis conserved
hypothetical protein proved not possible. However, clon-
ing of His-tagged versions of the other three proteins
was successful, followed by their production in E. coli
BLR(DE3) and subsequent purification (Fig 5).
Titration ELISA assays with dilutions of sera from all
donors were performed for each of the purified proteins.
While the thrombin inhibitor as well as the ubiquitin lig-
ase did not reveal any specific reactivity to any donor
serum as compared to a BSA negative control, the
metalloprotease was clearly recognized by the sera from
donors 1, 2 and 8 (Fig 6). Furthermore, sera from all
other donors did not show specific binding of IgG anti-
bodies compared to a BSA negative control (data not
shown). This finding strongly suggests the immunogenic
character of the metalloprotease and clearly shows the
presence of specific antibodies in the sera from three do-
nors, two of which self-reported as tick-bite sensitized.
Discussion
Due to their ability to transmit pathogens, ticks pose sig-
nificant risks to humans and domestic animals resulting
in public health concerns and significant economic
losses [1]. Current treatments to relieve tick burdens in
endemic areas are mostly based on application of acari-
cides. This strategy, however, has negative impacts on
the environment and agriculture, and raises concerns
about the development of resistances [5]. Development
of a broad-spectrum tick protective vaccine represents a
promising alternative. Based on the phenomenon of ac-
quired tick immunity [13], vaccination with molecules
present in tick saliva appears to be a most sound public
health approach [5]. The goal of this study was to iden-
tify I. scapularis salivary antigens that could serve as
novel tick protective vaccine candidates for humans. A
phage display approach was adapted to identify these pro-
teins. The screening was designed to identify I. scapularis
salivary antigens recognized by antibodies present in hu-
man blood sera.
This study reports the first use of antibodies from hu-
man blood sera as probes for detecting immunogenic sal-
ivary proteins. In former studies antibodies from rabbits
were successfully used [20]. However, studies attempting
to identify salivary proteins recognized by the human
Fig 4 Result of a screening ELISA after three rounds of panning with SGH specific antibodies from donor 8. Monoclonal antigen-displaying phage
were immobilized in the wells of a microtiter plate and screened for reactivity with the enriched serum antibodies. Letter-Number combinations
on the x-axis represent the wells of the plate. Red bar represents immobilized Hyperphage, not displaying any peptide, as the negative control.
Green bars represent detection of M13 phage as a positive control for phage immobilization
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immune system are lacking. The prospect of utilizing hu-
man samples comes with some disadvantages compared
to animal sera derived from controlled experiments. First,
the availability of tick-naive serum donors is critical since
donors reporting as tick-bite naive might have been un-
knowingly exposed to ticks. In contrast, tick-bite sensi-
tized donors provide highly relevant sera. Importantly, the
time interval since last tick exposure plays an essential role
for the titers of specific antibodies in sera. This point likely
explains the differences observed in IgG binding to saliv-
ary gland homogenate between individual donors in this
study. The limitation of low antibody titers was overcome
by enrichment of specific anti-SGH antibodies.
After establishing the screening protocol using human
sera, eight unique oligopeptide phage clones were se-
lected, showing significant reactivity to whole sera as
well as enriched anti-tick specific antibodies from three
tick-bite sensitized donors.
Among the proteins identified in this screening, the most
promising candidate is metalloprotease 1 (MP1). MP1 has
a theoretical molecular weight of 37 kDa, a conserved
zinc-binding domain as well as twelve highly conserved
cysteine residues. Apart from this protein being secreted
into the extracellular space, MP1 has been described before
as potentially immunogenic [34]. Therefore, these results
confirm the suggested immunogenic character of MP1.
Furthermore, MP1 has been stated to have fibrin(ogen)lytic
activity as well as gelatinase activity [34]. Ticks could be
utilizing these biochemical activities to counteract haemo-
stasis or act in destruction of host extracellular matrix
(ECM). Interestingly, it has been reported that Borrelia
burgdorferi upregulates host metalloproteases in order to
damage host ECM and facilitate infection [35]. This finding
suggests a direct impact of tick feeding on pathogen trans-
mission through compromising host defense. The selected
oligopeptide of MP1 is located directly at the beginning of
the cysteine-rich region and just 9 amino acids away from
the zinc-binding domain. Accordingly, it is tempting to
speculate that binding of an antibody to MP1 might have
direct negative influence on the enzymatic function and/or
enzyme-substrate interaction through steric hindrance.
If considering MP1 as a potential vaccine candidate,
multi-species protection is of high interest [36]. Interest-
ingly, MP1 has very close homologs in other tick species
such as I. pacificus and I. ricinus, the latter being the
most prevalent tick vector of Lyme borreliosis in Europe.
Salivary gland metalloproteases identified in I. ricinus
termed Metis (Metalloptotease from Ixodes ricinus) have
been described previously and were shown to have good
vaccination capacity. Furthermore, RNAi-based knock-
down of Metis proteins in I. ricinus revealed increased tick
mortality [37, 38]. Interestingly, sequence comparison of
Table 2 Summary of immune-recognized peptides in this study. Information is given on the targets identified as well as the
frequency at which they were found in the 27 clones above detection threshold after the third round of panning
Description Accession Number Frequency Derived from Donor #
Ixodes scapularis conserved hypothetical protein, mRNA XM_002402723.1 8/27 8
Ixodes scapularis solute carrier, putative, mRNA XM_002416261.1 2/27 8
Ixodes scapularis thrombin inhibitor, putative, mRNA XM_002408067.1 2/27 8
Ixodes scapularis ubiquitin protein ligase, putative, mRNA XM_002412768.1 2/27 8
Ixodes scapularis salivary gland metalloprotease mRNA, complete cds AY_264367.1 9/27 2 and 8
Ixodes scapularis 60S ribosomal protein L14, putative, mRNA XM_002403042.1 2/27 2 and 8
Ixodes scapularis E3 ubiquitin protein ligase Bre1, putative, mRNA XM_002434300.1 1/27 8
Ixodes scapularis DNA ligase, putative, mRNA XM_002406537.1 1/27 2
Table 3 Amino acid sequences of the peptides displayed as fusions of pIII on M13 phage during panning and subsequent
screening ELISA
Description Accession Number Peptide Sequence
Ixodes scapularis conserved hypothetical protein, mRNA XM_002402723.1 LANVLVVATTVGVLHRVHGDTADLG
Ixodes scapularis solute carrier, putative, mRNA XM_002416261.1 WD*IGERVGESLAVPSPTSCISCTSSSHFKHNSLFSGVLILGSVQVE
Ixodes scapularis thrombin inhibitor, putative, mRNA XM_002408067.1 HDPDAVLFMGSIRE
Ixodes scapularis ubiquitin protein ligase, putative, mRNA XM_002412768.1 SKPGTFWPAVSVPRCCSQGNR
Ixodes scapularis salivary gland metalloprotease mRNA, complete cds AY_264367.1 KNMSEWVNGTLQSWTGGYAYVGTACSEWRVGMCEDRPT
Ixodes scapularis 60S ribosomal protein L14, putative, mRNA XM_002403042.1 MRIPHSTSTKVVRR
Ixodes scapularis E3 ubiquitin protein ligase Bre1, putative, mRNA XM_002434300.1 LPPSHRRVCTSVCDCGVHLRSQVLRVSPPRRTLLVPSKKRSCFECT
Ixodes scapularis DNA ligase, putative, mRNA XM_002406537.1 LAKSDKDSVTHVLKGDHVKLK
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MP1 with Metis1 reveals 84 % identity between the two
proteins on amino acid level. Despite having low homology
to MP1 another vaccination study performed in rabbits
using a metalloprotease from Haemophysalis longicornis
also revealed good vaccination efficiency [39]. These find-
ings, combined with the high degree of homology between
Metis proteins and MP1, strongly favor MP1 as a putatively
effective, multi-species vaccine candidate.
Besides metalloprotease MP1, the phage display strat-
egy identified a putative thrombin inhibitor as another
immunogenic tick salivary component. Unfortunately,
the immunogenic character of this protein could not be
M CL SN 1W 2W 3W PBSW 1E 2E 3E M CL SN 1W 2W 3W PBSW 1E 2E 3E
M CL SN1 1W 2W 3W PBSWSN2 M 1E 2E 3E
A B
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37 kDa
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Thrombin Inhibitor
Ubiquitin Ligase
Fig 5 Western Blot analysis of recombinantly expressed tick salivary proteins metalloprotease 1 a, Ubiquitin Ligase b and Thrombin Inhibitor c. All
three proteins were expressed as His-Tag fusion proteins and detected with an anti-His-Tag antibody. Abbreviations represent the following: CL
crude lysate, SN supernatant after binding to Ni-Sepharose, 1 W first wash fraction, 2 W second wash fraction, 3 W third wash fraction, PBSW PBS
wash fraction, 1E first eluted fraction, 2E second eluted fraction, 3E third eluted fraction
10-3 10-2 10-1 100
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
Donor 1
Donor 2
Donor 8
Donor 1 control
Donor 2 control
Donor 8 control
Serum Dilution
A
bs
or
ba
nc
e 
45
0 
nm
Fig 6 Titration ELISA to determine reactivity of IgG from donor sera with I. scapularis metalloprotease (MP). MP was recombinantly produced in E.
coli BLR(DE3), purified and immobilized in the wells of a microtiter plate. Reactivity of sera from donors 1, 2 and 8 is depicted (solid lines). As
negative controls, sera were screened against blocked wells without recombinant MP (dashed lines)
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confirmed via recombinant expression and ELISA. This
shortcoming was potentially due to limitations in the
bacterial expression system, including incomplete/im-
proper folding or absence of post-translational modifica-
tions in the expressed protein. However, it is reasonable
to speculate that a thrombin inhibitor provides a major
benefit in tick feeding. Accordingly, counteracting the
thrombin inhibitor through antibodies would be a sens-
ible host response to tick feeding. Based on sequence
similarity, the identified protein can be placed in the ser-
pin family of protease inhibitors, suggesting its ability to
interfere with the blood clotting cascade and other pro-
tease cascades involved in inflammation such as comple-
ment activation or catabolism of phagocytosed proteins.
Interestingly, a recent publication identifies a thrombin
inhibitor from I. scapularis, which is reported to inhibit
not only thrombin but also Factor Xa and cathepsin G,
revealing activities against haemostasis and inflammatory
responses [40]. This report bolsters significance and
credibility to the thrombin inhibitor identified in this
screen as a potential vaccine target.
Excluding the metalloprotease and the thrombin inhibi-
tor mentioned previously, all other binders identified in
this work are intracellular proteins. While it may seem
counterintuitive to envision intracellular proteins as poten-
tial vaccine candidates, just such a tick ribosomal protein
has recently been suggested [41]. The well documented,
dynamic nature of salivary gland protein expression during
feeding [11, 42] necessitates a synchronization between cell
proliferation and cell death; dying cells can leak intra-
cellular components into the surrounding fluids, thus
enabling host contact and initiation of the adaptive im-
mune response. Antibodies binding these displaced
intracellular proteins may form immune complexes at
the tick-bite site and help recruit other cells of the im-
mune system such as neutrophils or macrophages [17],
thereby providing a mechanism for inducing inflamma-
tion at a site that is otherwise strongly immune-
suppressed through the activities of many other of the
tick salivary proteins. Of note, a recent study using a
T7 phage display based approach to identify the tick
saliva immune-proteome reports a broad range of pro-
teins, secreted and intracellular, to be putatively im-
munogenic [43].
The discovery of Metalloprotease 1 appears highly
promising due to its published recognition as an im-
munogenic antigen and the high efficiency of other
tick metalloproteases in stimulating a vaccination re-
sponse [34, 37–39]. All identified proteins in this study
represent potentially important new tools in solving
the tick problem; they may prove not only for their
strong potential as anti-tick vaccine candidates but
also for diagnostic purposes as biomarkers of vector
tick exposure.
Conclusion
In this work, MP1 of I. scapularis was identified as im-
munogenic protein. This protein was hypothesized as
immunogenic in former publications. Because MP1 is
highly homologous in all Ixodes species, this protein is
an interesting biomarker and potential candidate for
vaccine development.
Materials and Methods
Tick rearing and salivary gland homogenate
Ixodes scapularis ticks were reared as described previ-
ously [44]. Adult ticks were collected from nature to cre-
ate immature tick colonies. One hundred larvae from
each egg batch were screened by PCR using pathogen-
specific primers for Borrelia burgdorferi and Borrelia
miyamotoi. Certified pathogen-free larval stage ticks
were blood fed on hamsters or white-footed mice to pro-
mote molting. All unfed nymphal ticks were maintained
at 23 °C and >90 % relative humidity under 14 h light/
10 h dark photoperiod before infesting hosts. Methods
for generating uninfected tick colonies, including animal
care, followed protocols approved by the Institutional
Animal Care and Use Committee (IACUC) at the the
University of Rhode Island (URI). Comprised of faculty
members, an Attending Veterinarian, and at least one
representative of the public (not affiliated with URI), the
IACUC oversees all URI research and instruction that
involves vertebrate animals, in order to ensure that the
highest ethical and animal welfare standards are met.
URI IACUC has approved all animal use protocols for
generating uninfected ticks, ensuring compliance with
federal regulations. Additionally, IACUC has inspected
all animal facilities and laboratories in which this re-
search was completed. All URI researchers are trained
and certified yearly to ensure compliance with federal
regulations regarding animal welfare. Pathogen-free
nymphs were allowed to feed for 18 h prior to dissection
for salivary glands. Partially-fed ticks were dissected in
ice-cold phosphate buffered saline (PBS) [45] within 4 h
of being removed from the host animal. After removal,
glands were washed in the clean buffer and tissues were
stored at −70 °C in PBS until cell lysis by sonication.
Protein concentration was detected by UV nanodrop
quantification (ThermoScientific, ND-1000).
mRNA isolation from salivary gland and SMART cDNA
synthesis
mRNA from tick salivary glands was isolated using the
Illustra mRNA purification Kit (GE Healthcare, Munich,
Germany) according to the supplier’s instructions. Subse-
quently, the mRNA obtained was further concentrated
using the RNeasy Mini Elute clean-up Kit (Qiagen, Hilden,
Germany) according to the supplier’s instructions.
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Tick salivary gland derived mRNA was used to gener-
ate double-stranded cDNA. 13 μl mRNA (at least 25 ng)
were mixed with 1 μl 3′ SMART CDS Primer II A
(12 μM) (5′ AAGCAGTGGTATCAACGCAGAGTACT
(30)AT 3′) and 1 μl SMART II A Oligonucleotide
(12 μM) (5′ AAGCAGTGGTATCAACGCAGAGTACG
CGGG 3′). The mixture was incubated at 72 °C for
2 min and placed on ice for 2 min. Subsequently, 4 μl 5x
First Strand Buffer (Life Technologies, Darmstadt), 0.2 μl
DTT, 1 μl dNTP Mix (10 mM each) and 1 μl M-MLV
reverse transcriptase (Life Technologies, Darmstadt)
were added and the mixture was incubated at 37 °C for
1 h yielding first strand cDNA. For second strand syn-
thesis a long distance PCR was performed using 2 μL
first strand cDNA, 10 μL ExTaq buffer (Takara), 4 μL
dNTP mix (2.5 mM each), 2 μL 5′ PCR Primer IIA
(12 μM) (5′ AAGCAGTGGTATCAACGCAGAGT 3′),
0.25 μL ExTaq DNA Polymerase (Takara), 36.75 μL
dH2O. The PCR reaction was performed for 24 cycles
(15 s 95 °C, 30 s 65 °C, 6 min 72 °C) followed by a
10 min final synthesis step. The PCR products were puri-
fied using the Nucleospin Extract 2 Kit (Macherey-Nagel,
Düren, Germany).
Salivary gland library construction
To generate blunt ended DNA fragments suitable for
cloning into pHORF3 [28] a restriction enzyme digest
using the blunt end cutting enzymes AfeI, AluI and
CviKI-1 (NEB, Frankfurt, Germany) was performed.
30 μl SMART cDNA (~1.7 μg) were mixed with 1.25 U
of each of the restriction enzymes, 10 μL NEBuffer 4
(NEB), 10 μL 10xBSA solution (NEB) in a total volume
of 100 μl. The digestion was incubated at 37 °C for
10 min followed by a heat inactivation at 65 °C for
20 min.
The phagemid vector pHORF3 was linearized by di-
gestion with PmeI (NEB). Incubation was performed at
37 °C over night followed by heat inactivation at 65 °C
for 10 min. Subsequently, the vector was dephosphory-
lated with 0.5 μl calf intestinal phosphatase (CIP) (NEB)
at 37 °C for 30 min. Linearized and dephosphorylated
vector was purified using the NucleoSpin Kit (Machery
Nagel).
For library cloning, a 10x fold molar excess of cDNA
was cloned into 500 ng of linearized pHORF3. The
ligation was performed in 60 μL volume with 3U T4
DNA Ligase (Promega, Mannheim, Germany) at 16 °C
over night. Ligation mixture was added to 50 μl electro-
competent E. coli TOP 10 F’ cells (Life Technologies)
and incubated on ice for 5 min. Subsequently the DNA-
cell suspension was filled into pre-chilled cuvettes and
electroporation was performed with a pulse of 1.7 kV.
1 ml SOC [45] medium with a temperature of 37 °C was
added immediately and the cells were incubated at 37 °C
and 600 rpm for 1 h. Finally, the whole cell suspension
was plated on 2xYT agar [45] plates supplemented with
0.1 M glucose and 100 μg/mL ampicillin. Plates were in-
cubated over night at 37 °C. Colonies were floated off
the agar plates with 40 ml 2xYT medium. The resulting
cell suspension was centrifuged at 3220 x g, 4 °C for
15 min. The pellet was resuspended in 2xYT medium con-
taining 20 % glycerol and the sample was stored at −80 °C.
Library packaging
400 ml 2xYT medium supplemented with 0.1 M glucose
and 100 μg/mL ampicillin (2xYT-GA) were inoculated
with 1 ml antigen library glycerol stock and bacteria were
grown at 37 °C and 250 rpm until OD 600 = 0.5. 25 ml
from that culture were transferred to 50 ml reaction tubes
and infected with 2.5 x 1011 CFU Hyperphage [30, 31, 33].
Infection was achieved by incubating at 37 °C for 30 min
followed by a second incubation for 30 min at 37 °C and
250 rpm. After centrifugation at 3220 x g for 10 min the
cell pellet was resuspended in 400 ml 2xYT supplemented
with 100 μg/mL ampicillin and 50 μg/mL kanamycin
(2xYT-AK) and the culture was incubated 24 h at 30 °C
and 250 rpm. The cell suspension was centrifuged at 6000
x g, 4 °C for 20 min and the supernatant was transferred
into a fresh tube. For precipitation of the phage 1/5 vol-
ume PEG/NaCl (20 % (w/v), 2.5 M NaCl) was added to
the suspension which was subsequently incubated at 4 °C
over night. Phage were pelleted by centrifugation at 10,000
x g, 4 °C for 1 h. The supernatant was discarded and the
pellet was resuspended in 20 ml phage dilution buffer
(10 mM Tris, 20 mM NaCl, 2 mM EDTA) and filter-
sterilized (pore size 0.45 μm). Again 1/5 volume PEG/
NaCl was added and the sample was incubated on ice for
1 h followed by a centrifugation at 20,000 x g, 4 °C for
20 min. The resulting pellet was resuspended in 5 ml
phage dilution buffer and the oligopeptide phage particles
were stored at 4 °C.
Enrichment of serum antibodies against salivary gland
homogenate (SGH)
The study was performed in accordance with the Declar-
ation of Helsinki and was conducted in accordance with
University of Rhode Island’s Institutional Review Board,
Approval number HU1011-041. All voluntary donors
were informed about the project and gave their informed
consent. To enrich serum antibodies specific for salivary
gland homogenate (SGH) 2 x 107 Carboxy Beads (Dyna-
beads, Life Technologies) were washed twice with 1 ml
PBST (PBS, 0.05 % Tween20) and twice with 0.5 ml
NaAc buffer (pH 4.5) by rotating for 5 min. Next, 100 μl
EDC and 100 μl NHS were added and the beads were
rotated for 10 min at room temperature followed by an-
other two washing steps with 0.5 ml NaAc buffer
(pH 4.5) [45] and 5 min of rotation each. 20 μg SGH
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(1 μg/106 beads) were diluted in 200 μl NaAc buffer and
incubated with the beads under rotation for 20 min at
room temperature. Subsequently, the beads were washed
three times with 1 ml PBST followed by a 2 h rotation
with 1 ml 100 mM ethanol amine. After this blocking
step the beads were washed three times with 1 ml PBST,
once with 1 ml PBS followed by an equilibration in 1 ml
0.1 M glycine/HCl pH 2.2. The beads were washed an-
other three times with 1 ml PBS and incubated with
400 μl of a 1:1 serum-PBS dilution under rotation at 4 °C
over night. Next, the beads were washed three times with
1 ml PBS and the serum antibodies were eluted by incuba-
tion with 150 μl 0.1 M glycine/HCl pH 2.2 under rotation
for 15 min at room temperature. The supernatant was
neutralized by addition of 45 μl 0.5 M Tris–HCl pH 8 and
brought to a total volume of 300 μl by adding PBS. The
eluted antibodies were stored at 4 °C.
Selection of immunogenic oligopeptides (panning)
For selection of immunogenic oligopeptide-phage mouse
α-human IgG (Fc specific) (I6760, Sigma, Munich,
Germany) monoclonal antibody was diluted 1:5,000 in
carbonate buffer [45] and 100 μl were immobilized in a
Costar polystyrole microtitre plate (MTP) well (Corning,
Germany) at 4 °C over night. In parallel, 50 μL SGH
enriched antibody fraction and 1x1011 Hyperphage parti-
cles were pre-incubated at 4 °C over night in 150 μL PBST
supplemented with 2 % (w/v) skim milk powder (2 %
MPBST). The MTP well with the capture antibody was
blocked with 350 μl 2 % MPBST for 1.5 h at room
temperature followed by three washing steps with
PBST using an ELISA washer. The pre-incubated pa-
tient serum was transferred into the MTP well with the
blocked capture antibodies and incubated at room
temperature for 2 h followed by three washing steps
with PBST. 200 μl oligopeptde library phage or phage
from the previous panning round were filled into the
MTP well and incubated for 2 h at room temperature.
This incubation was followed by 10 x N stringent wash-
ing steps with PBST where N = number of the panning
round. Bound phage particles were eluted by addition
of 200 μl Trypsin solution (10 μg/ml in PBS) and incu-
bation at 37 °C for 30 min. 190 μl of the eluted phage
were used to re-infect E. coli TOP10F’ for phage ampli-
fication. The remaining 10 μl were used for titration of
the eluted phage.
For the amplification of eluted phage 50 mL 2xYT-T
medium were inoculated with 200 μl of an E. coli
TOP10F’ starter culture and the culture was grown at
37 °C and 250 rpm to OD600 = 0.5. The eluted phage
were added to 20 mL of the culture and incubated at
37 °C for 30 min followed by a second incubation for
30 min at 37 °C and 250 rpm. The re-infected cells were
pelleted by centrifugation at 3220 x g for 10 min. The
pellet was re-suspended in 250 μl 2xYT medium, plated
on a 15 cm 2xYT-GA agar plate and incubated at 37 °C
over night. Colonies were floated off the agar plate using
5 ml 2xYT medium. 250 μl of the cell suspension were
used to inoculate 50 ml 2xYT-GA medium to OD600 =
0.05 to 0.09. The culture was subsequently grown at 37 °C
and 250 rpm to OD600 = 0.5. 5 ml culture were infected
with 5 x 1011 Hyperphage particles by incubation at 37 °C
for 30 min followed by a second incubation for 30 min at
37 °C and 250 rpm. The cells were pelleted at 3220 x g for
10 min and the pellet was resuspended in 30 ml 2xYT-AK
followed by an incubation at 30 °C and 250 rpm overnight.
Produced oligopeptide phage were pelleted as outlined
above. The phage pellet was re-suspended in 500 μl phage
dilution buffer and stored at 4 °C until it was used in the
next panning round. 10 μl were used to titer the amplified
phage. In each selection three rounds of panning were
performed.
Screening Elisa
To produce monoclonal oligopeptide phage particles,
polypropylene MTPs (96 Well, flat bottom, Sarstedt,
Germany) were filled with 150 μl 2xYT-GA medium and
each well was inoculated with a single colony resulting
from the third panning round and incubated over night
at 37 °C and 300 rpm. A new MTP was filled with
150 μl 2xYT-GA medium and each well was inoculated
with 10 μl over night culture from the respective well of
the master MTP and incubated for exactly 2 h at 37 °C
and 300 rpm. Next, 5 x 109 Hyperphage particles were
added per well and the MTP was incubated at 37 °C for
30 min, followed by a second 30 min incubation at 37 °C
and 300 rpm. Subsequently, bacteria were pelleted by
centrifugation at 3220 x g for 10 min and the super-
natant was discarded. The pellets were re-suspended in
150 μl 2xYT-AK and the MTP was incubated at 37 °C
and 300 rpm over night. On the next day, the MTP was
centrifuged at 3220 x g for 10 min and the phage super-
natants were transferred to a new polypropylene MTP.
40 μl PEG/NaCl were added to each well and the plate
was incubated on ice at 4 °C over night. Phage particles
were pelleted by centrifugation at 3220 x g for 1 h at 4 °C.
The supernatants were discarded and the phage pellets
were re-suspended in 150 μl phage dilution buffer. The
plate was centrifuged again at 3220 x g for 10 min to pellet
remaining bacteria and the supernatants were transferred
to a new polypropylene MTP.
For the screening ELISA, mouse α-M13 capture anti-
body (B62-FE2, Progen, Heidelberg, Germany) was di-
luted 1:400 in 100 μL carbonate buffer and incubated in
Costar MTP wells over night at 4 °C. In parallel, 50 μL
serum, 1x1011 Hyperphage particles were pre-incubated
at 4 °C over night in 100 μL 2 % MPBST. The wells were
blocked with 2 % MPBST for 1.5 h at room temperature
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followed by three washing steps with PBST using an
ELISA washer. 50 μl monoclonal oligopeptide phage
and 50 μl 2 % MPBST were transferred into the well
with the anti-M13 capture antibody and incubated at
room temperature for 2 h. As negative control 1x1010
Hyperphage were used. After three washing steps with
PBST using an ELISA washer 100 μl pre-incubated
serum were filled into each well and incubated for 2 h
at room temperature followed by three washing steps
with PBST. Bound human serum antibodies were de-
tected with goat α-human IgG (Fc specific) conjugated
with horseradish peroxidase (A0170, Sigma) diluted
1:70,000 in 2 % MPBST for 1 h at room temperature.
As positive control mouse α-M13 HRP conjugate anti-
body (GE Healthcare) diluted 1:40,000 in 2 % MPBST
was used. Visualization was performed with TMB
(3,3′,5,5′-tetramethylbenzidine) substrate. The staining
reaction was stopped by adding 100 μL 1 N sulphuric
acid. The absorbance at 450 nm and scattered light at
620 nm were measured and the 620 nm value was sub-
tracted using a SUNRISE microtiter plate reader (Tecan,
Crailsheim, Germany).
Cloning of metalloprotease 1, ubiquitin ligase and
thrombin inhibitor
The cDNA of the proteins was amplified by PCR using
the following oligonucleotide primers: for the metallo-
protease 1 MHMetalI_f1 (5′ gcgtg gctagc cat cat cat cac
cat cac agc tac aag atc ccc ttg g 3′) and MHMetall_r1
(5′ cgcac gcggccgc tca tta gtc atc ttt gct tat ttt gat atc g
3′), for the ubiquitin protein ligase ANFubiprotlig_f2 (5′
gcgtg gctagc gag gcg cag tac aac ctc c 3′) and ANFubi-
protlig_r1 (5′ cgcac gcggccgc ctt aaa agt gat ttg tgc agc
3′) and for the thrombin inhibitor ANFthrominhi _f2
(5′ gcgtg gctagc cac cag gaa ggg ga ctt caa gat ggg 3′)
and ANFthrominhi _r1 (5′ cgcac gcggccgc gag ctc acg
gat gga tcc c 3′). The PCR product of the metallopro-
tease 1 was cloned into pET21A+ and the PCR products
of the ubiquitin protein ligase and the thrombin inhibi-
tor were cloned into pET21A + −pelB, using NheI and
NotI restriction sites. After ligation the plasmids were
transformed into E. coli BLR-DE3. Positive clones were
identified by colony PCR using the oligonucleotide primers
MHpET21_f1 (5′ GAGCGGATAACAATTCCCC 3′) and
MHpET21_r1 (5′ GCAGCCAACTCAGCTTCC 3′).
Production of metalloprotease 1 in E. coli
250 mL 2xTY-GA medium were inoculated with 5 mL
overnight culture and cultivated to an OD600 = 0.8 at
37 °C and 250 rpm. The expression was induced with
1 mM IPTG (final concentration) and incubated for 4 h
at 22 °C and 220 rpm. Cells were harvested by centrifu-
gation at 4,400 x g for 15 min and 4 °C. Lysis was per-
formed with 1 mg/mL lysozyme and 5 μg/mL DNAseI
in 20 mL His-tag binding buffer pH8.0 (20 mM
Na2HPO4, 0.5 M NaCl) supplemented with 10 mM
Imidazole for 15 min at 30 °C followed by 4 min sonic-
ation (40 % power, 30 s pulse, 30 s pause) (Sonotrode
MS72, Bandelin, Berlin, Germany). The suspension was
centrifuged for 15 min at 4 °C and 27,000 x g. The pellet
was washed twice with His-tag binding buffer supple-
mented with 10 mM Imidazole and 0.5 % Triton X-100.
Finally, the pellet was resuspended in His-tag binding
buffer, supplemented with 8 M urea and centrifuged for
30 min at 4 °C and 27,000 x g. The His-tagged metallo-
protease in the supernatant was purified under denatur-
ing conditions with FastFlow Sepharose (GE Healthcare)
loaded with nickel. The Sepharose was washed with
10 mM, 30 mM and 60 mM imidazole (20 mM
Na2HPO4, 0,5 M NaCl, 10, 30 or 60 mM Imidazol). For
elution, 5 mL 100 mM EDTA in PBS supplemented with
8 M urea were used. The purified proteins were stored
at −20 °C.
Production of ubiquitin ligase and thrombin inhibitor in
E. coli
250 mL 2xTY-GA medium were inoculated with 5 mL
overnight culture and cultivated to an OD600 = 0.8 at
37 °C and 250 rpm. The expression was induced with
1 mM IPTG (final concentration) and incubated for 4 h
at 22 °C and 220 rpm. Cells were harvested by centrifu-
gation at 4,400 x g for 15 min and 4 °C. The Pellet was
resuspended in 25 ml ice cold PE buffer (500 mM Suc-
crose, 100 mM Tris pH8.0, 1 mM EDTA) and incubated
on ice for 20 min with stirring or shaking. The suspen-
sion was centrifuged for 30 min at 4 °C and 27,000 x g.
The supernatant (periplasmatic preparation (PPP)) was
stored on ice. The pellet was resuspended in 25 ml ice
cold 5 mM Mg2SO4 and incubated on ice for 20 min
with stirring or shaking. The suspension was centrifuged
for 30 min at 4 °C and 27,000 x g. The supernatant (os-
motic shock preparation (OSP)) was pooled with the
PPP. His-tag binding buffer pH 8.0 (20 mM Na2HPO4,
0.5 M NaCl) supplemented with 10 mM Imidazole was
added 1:1 to the pooled fraction. The proteins were puri-
fied with FastFlow Sepharose (GE Healthcare) loaded
with nickel. The Sepharose was washed with 10 mM,
20 mM and 30 mM imidazole (20 mM Na2HPO4, 0,5 M
NaCl, 10, 20 or 30 mM Imidazol). For elution, 5 mL
100 mM EDTA in PBS was used. The purified proteins
were stored at −20 °C.
Titration ELISA
200 ng metalloprotease 1 were coated to 96 well microti-
ter plates (MaxiSorp, Nunc) in 50 mM NaHCO3 pH 9.6
overnight at 4 °C. In parallel, human sera were pre-
incubated in PBST supplemented with 2 % (w/v) BSA.
After coating, the wells were washed three times with
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PBST and blocked with 2 % MPBST for 1.5 h at RT,
followed by three washing steps with PBST. Human sera
were diluted in 100 μL 2 % MPBST and incubated in the
metalloprotease 1 coated plates for 2 h at RT, followed by
three PBST washing cycles. Bound human IgGs were de-
tected with goat anti-human IgG HRP conjugate (1:78,000
in 2 % MPBST) (A0170, Sigma). The visualization was
performed with TMB as described above.
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